Prostatilen vs Vilon

Overview

Prostatilen and Vilon are both studied in the peptide research space.

Prostatilen: A peptide complex extracted from bovine prostate glands, developed in Russia and registered as a pharmaceutical for prostatitis treatment.

Vilon: A synthetic dipeptide (Lys-Glu) developed by Russian scientist Vladimir Khavinson as part of the peptide bioregulation framework.

Evidence Comparison

Vilon evidence scope (September 9, 2026)

Vilon’s selected bibliography contains 25 publications: five human-containing reports, 17 preclinical experimental reports and three review or synthesis documents. These are publication counts, not five independent clinical trials or a complete literature census. Human cell cultures belong to the preclinical group; some reports examine several peptides. Possible cohort reuse, including the two diabetes reports, remains unresolved. Counts and inherited catalogue grades do not establish clinical equivalence or superiority between these compounds.

Three indexed reports describe adjunctive Vilon in diabetes or colorectal-cancer care. One diabetes paper is indexed as a randomized controlled trial, but the retained abstracts do not provide sufficient allocation, sample-size, safety or outcome detail to establish reliable clinical benefit. Diabetes report, second diabetes report, colorectal-cancer report.

Two 2022 publisher documents report oral supplement use: a 520-person convalescence account and a 98-person gastritis study alongside standard eradication therapy. Reporting and product-characterization limitations remain. The gastritis study found no statistically significant gastric pH changes; its symptom-response counts conflict with the reported means. The convalescence immune-marker table reports within-group significance, which alone does not establish a treatment effect versus placebo. These reports do not establish oral pharmacokinetics or routine immune-support efficacy. Convalescence report, gastritis report.

The May 2025 dentistry publication is a review of older clinical material, not a new trial. Its Vilon, combined-treatment and mixed-peptide accounts cannot be counted as independently confirmed native-Vilon cohorts. Dentistry review.

Safety is inadequately characterized in people. Animal findings include increased mammary-tumour incidence in a HER2/neu mouse model and reduced survival with synchronous Vilon and cyclophosphane in a different mouse cancer experiment. These findings do not quantify human risk, but they preclude a blanket safety or combination-compatibility claim. HER2/neu mouse report, mouse combination report.

Aspect	Prostatilen	Vilon
Evidence Level	Moderate	Clinical certainty not formally graded
Human Studies	8	5 human-containing reports; independence unresolved
Preclinical Studies	7	17 experimental reports; mixed models
Total Sources	18	25 selected publications

Key Differences

Aspect	Prostatilen	Vilon
Category	Hormonal	Immune
Evidence Strength	Moderate	Clinical certainty not formally graded
Total Sources	18	25 selected publications
Human Studies	8	5 human-containing reports; independence unresolved

Summary

• Prostatilen: Moderate evidence with 18 total sources (8 human)
• Vilon: 25 selected publications, including five human-containing reports; clinical benefit and safety remain uncertain.

---

This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.